Anat Fisher

ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 12

Top Venues

Pharmacoepidemiology and drug safety

Gastroenterology research and practice

PloS one

The Journal of rheumatology

University of British Columbia Faculty of Medicine

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of British Columbia Faculty of Medicine Aug 01 2014

Canada

Research associate :: Anesthesiology, Pharmacology and Therapeutics

Publications

Anat Fisher, Jason D Kim, Colin R Dormuth
Monitoring a Mandatory Nonmedical Switching Policy from Originator to Biosimilar Infliximab in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort Study. Gastroenterology research and practice 2023 (2023)
Greg Carney, Malcolm Maclure, David M Patrick, Anat Fisher, Dana Stanley, Ken Bassett, Colin R Dormuth
A cluster randomized trial assessing the impact of personalized prescribing feedback on antibiotic prescribing for uncomplicated acute cystitis to family physicians. PloS one 18 (7) (2023)
Anat Fisher, Jason D Kim, Colin R Dormuth
Monitoring a Mandatory Nonmedical Switching Policy from Originator to Biosimilar Infliximab in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort Study. Gastroenterology research and practice 2023 (2023)
Anat Fisher, Jason D Kim, Greg Carney, Colin R Dormuth
Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept-a cohort study in British Columbia. BMC rheumatology 6 (1) (2022)
Anat Fisher, J Michael Paterson, Brandace Winquist, Fangyun Wu, Pauline Reynier, Samy Suissa, Matthew Dahl, Zhihai Ma, Xinya Lu, Jianguo Zhang, Colette B Raymond, Kristian B Filion, Robert W Platt, Carolina Moriello, Colin R Dormuth, null null
Patterns of antiemetic medication use during pregnancy: A multi-country retrospective cohort study. PloS one 17 (12) (2022)
Anat Fisher, Jason D Kim, Colin R Dormuth
Rapid monitoring of health services utilization following a shift in coverage from brand name to biosimilar drugs in British Columbia-An interim report. Pharmacoepidemiology and drug safety 29 (7) (2020)
Antonios Douros, Lisa M Lix, Michael Fralick, Sophie Dell'Aniello, Baiju R Shah, Paul E Ronksley, Éric Tremblay, Nianping Hu, Silvia Alessi-Severini, Anat Fisher, Shawn C Bugden, Pierre Ernst, Kristian B Filion, null null
Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study. Annals of internal medicine 173 (6) (2020)
Anat Fisher, Marie Hudson, Robert W Platt, Colin R Dormuth, null null
Tofacitinib Persistence in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study. The Journal of rheumatology 48 (1) (2020)
Colin R Dormuth, Anat Fisher, Greg Carney
A rapid monitoring plan following a shift in coverage from brand name to biosimilar drugs for rheumatoid arthritis in British Columbia. Pharmacoepidemiology and drug safety 29 (7) (2020)
Pierre Ernst, Matthew Dahl, Dan Chateau, Nick Daneman, Jacqueline Quail, Ingrid S Sketris, Anat Fisher, Jianguo Zhang, Shawn Bugden, null null
Comparative Effectiveness Of Fluoroquinolone Antibiotic Use In Uncomplicated Acute Exacerbations Of COPD: A Multi-Cohort Study. International journal of chronic obstructive pulmonary disease 14 (2019)
Anat Fisher, Greg Carney, Ken L Bassett, K Malcolm Maclure, Colin R Dormuth
Policy-induced selection bias in pharmacoepidemiology: The example of coverage for Alzheimer's medications in British Columbia. Pharmacoepidemiology and drug safety 28 (8) (2019)
Anat Fisher, Greg Carney, Ken Bassett, Colin R Dormuth
Tolerability of Cholinesterase Inhibitors: A Population-Based Study of Persistence, Adherence, and Switching. Drugs & aging 34 (3) (2017)

Anat Fisher.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Anat Fisher